BEIJING, Nov. 3, 2011 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release third quarter 2011 financial results on Thursday, November 17, 2011 after the market closes.
The Company will hold a conference call at 8:00 am ET on Friday, November 18, 2011 to discuss third quarter 2011 results. Listeners may access the call by dialing:
| United States toll free: | 1-855-500-8701 |
| United States toll: | 1-646-254-3515 |
| China toll free: | 400-1200654 |
| Hong Kong toll free: | 800-903737 |
| United Kingdom toll free: | 0800-0159724 |
| Conference ID: | 24534162 |
A telephone replay will be available beginning two hours after the conclusion of the call and will be available through December 2, 2011. Listeners may access the replay by dialing:
| United States toll free: | 1-866-214-5335 |
| International: | 1-718-354-1232 |
| Conference ID: | 24534162 |
A webcast will also be available through the Company's website www.nkbp.com. ;
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 3,000 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.